论文部分内容阅读
应用0.5％环孢霉素A(cyclosporin A,CsA)滴眼治疗穿透性角膜移植术后发生免疫排斥患者16例(16只眼),治愈9只眼,好转6只眼,无效1只眼。随访5～24个月,其中2只眼因停药复发,1只眼于拆线后复发,继续用药或增加给药次数后治愈。研究表明0.5％CsA滴眼剂治疗术前移植床条件较好,角膜移植术后发生免疫排斥的病例可得到良好疗效;而对术前移植床条件较差,角膜移植术后发生免疫排斥的病例有一定的疗效。作者对眼局部应用CsA治疗角膜移植排斥的疗效和作用机理进行了讨论。
Sixteen patients (16 eyes) with immunological rejection after penetrating keratoplasty were treated with 0.5% cyclosporin A (CsA) eye drops, 9 eyes were cured, 6 eyes were improved, 1 eye was ineffective . All the patients were followed up for 5-24 months. Two of them were relapsed after discontinuation of treatment. One patient had recurrence after suture removal and continued to receive medication or increase the number of dosing. Studies have shown that 0.5% CsA eye drops treatment of preoperative transplant bed conditions are good, immunosuppression after corneal transplantation in patients with cases of good effect can be obtained; and poor preoperative transplant bed conditions, immunological rejection after keratoplasty cases Have a certain effect. The authors discuss the efficacy and mechanism of CsA for the treatment of corneal graft rejection.